Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2)

References

• Zhan P, Pannecouque C, De Clercq E, et al. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. J Med Chem. 2016;59:2849–2878.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev. 2013;33(Suppl 1):E1- E72.
   PubMed Web of Science ®Google Scholar
• De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695–747.
   PubMed Web of Science ®Google Scholar
• Li D, Zhan P, De Clercq E, et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem. 2012;55:3595–3613.
   PubMed Web of Science ®Google Scholar
• Huang B, Kang D, Zhan P, et al. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. Expert Opin Drug Discov. 2015;10:1271–1281.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhan P, Li D, et al. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem. 2011;18:359–376.
   PubMed Web of Science ®Google Scholar
• Huang B, Kang D, Yang J, et al. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opin Ther Pat. 2016;26:281–289.
   PubMed Web of Science ®Google Scholar
• Liu N, Wei L, Huang L, et al. Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. J Med Chem. 2016;59:3689–3704.
   PubMed Web of Science ®Google Scholar
• Tian Y, Du D, Rai D, et al. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorg Med Chem. 2014;22:2052–2059.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhan P, Li Z, et al. Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. Eur J Med Chem. 2014;76:531–538.
   PubMed Web of Science ®Google Scholar
• Wang L, Tian Y, Chen W, et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. Eur J Med Chem. 2014;85:293–303.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen W, Zhan P, et al. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. Eur J Med Chem. 2014;87:52–62.
   PubMed Web of Science ®Google Scholar
• Huang B, Li C, Chen W, et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. Eur J Med Chem. 2015;92:754–765.
   PubMed Web of Science ®Google Scholar
• Huang B, Liang X, Li C, et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. Eur J Med Chem. 2015;93:330–337.
   PubMed Web of Science ®Google Scholar
• Li X, Chen W, Tian Y, et al. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. Eur J Med Chem. 2014;80:112–121.
   PubMed Web of Science ®Google Scholar
• Yang J, Chen W, Kang D, et al. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. Eur J Med Chem. 2016;109:294–304.
   PubMed Web of Science ®Google Scholar
• Meng Q, Chen X, Kang D, et al. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. Eur J Med Chem. 2016;115:53–62.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhan P, Daelemans D, et al. Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. Eur J Med Chem. 2016;121:352–363.
   PubMed Web of Science ®Google Scholar
• Sergeyev S, Yadav AK, Franck P, et al. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors. J Med Chem. 2016;59:1854–1868.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Pauly GT, Akram A, et al. Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. Retrovirology. 2016;13:11.
   PubMed Web of Science ®Google Scholar
• Patel RV, Keum YS, Park SW. Medicinal chemistry discoveries among 1,3,5-triazines: recent advances (2000-2013) as antimicrobial, anti-TB, anti-HIV and antimalarials. Mini Rev Med Chem. 2014;14:768–789.
   PubMed Web of Science ®Google Scholar
• Viira B, Selyutina A, Garcia-Sosa AT, et al. Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 2016;24:2519–2529.
   PubMed Web of Science ®Google Scholar
• Arien KK, Venkatraj M, Michiels J, et al. Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398. J Antimicrob Chemother. 2016;71:1159–1168.
   PubMed Web of Science ®Google Scholar
• Lee WG, Frey KM, Gallardo-Macias R, et al. Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2015;25:4824–4827.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem. 2009;16:3903–3917.
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Ren J, Tanaka H, et al. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J Med Chem. 1999;42:4500–4505.
   PubMed Web of Science ®Google Scholar
• Ferris RG, Hazen RJ, Roberts GB, et al. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2005;49:4046–4051.
   PubMed Web of Science ®Google Scholar
• Romines KR, Freeman GA, Schaller LT, et al. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem. 2006;49:727–739.
   PubMed Web of Science ®Google Scholar
• Ren J, Chamberlain PP, Stamp A, et al. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem. 2008;51:5000–5008.
   PubMed Web of Science ®Google Scholar
• Fattorusso C, Gemma S, Butini S, et al. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J Med Chem. 2005;48:7153–7165.
   PubMed Web of Science ®Google Scholar
• Das K, Bauman JD, Clark AD Jr., et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A. 2008;105:1466–1471.
   PubMed Web of Science ®Google Scholar
• Wan ZY, Yao J, Mao TQ, et al. Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue. Eur J Med Chem. 2015;102:215–222.
   PubMed Web of Science ®Google Scholar
• Li W, Li X, De Clercq E, et al. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. Eur J Med Chem. 2015;102:167–179.
   PubMed Web of Science ®Google Scholar